← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

Alport Syndrome

MONDO:0018965 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 34 citations openscientist · 47 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Alport syndrome is a hereditary basement-membrane disorder caused by pathogenic variants in COL4A3, COL4A4, and COL4A5, which disrupt assembly of the alpha3-alpha4-alpha5 type IV collagen network of the glomerular (and cochlear/ocular) basement membranes.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 95% mutations disrupt α3α4α5(IV) heterotrimer formation and basement membrane integrity, rendering the GBM vulnerable under filtration pressure, leading to haematuria and progressive injury.
Falcon names the same three COL4 genes and the alpha3-alpha4-alpha5(IV) heterotrimer defect as the primary causal mechanism of GBM failure.
DOI:10.23876/j.krcp.24.065
openscientist CONCORDANT 97% These mutations disrupt the assembly of the α3α4α5(IV) collagen network, a critical structural component of the glomerular basement membrane (GBM), cochlear basement membranes, and ocular basement membranes.
OpenScientist asserts the identical driver mechanism and extends it explicitly to cochlear and ocular basement membranes.
PMID:16895672

Alport syndrome occurs in X-linked (COL4A5), autosomal recessive (biallelic COL4A3/COL4A4), autosomal dominant (heterozygous COL4A3/COL4A4), and digenic forms, with the X-linked form the most common (~80-85% of cases).

UNANIMOUS INTEGRATED
genetic_factorepidemiology
ProviderStanceScoreEvidence
falcon CONCORDANT 80% XLAS is most common; one 2024 review reports
Falcon reports XLAS as the most common form (~80% XLAS, 10-15% ARAS in the cited 2024 review) and recognizes X-linked, autosomal recessive, autosomal dominant, and digenic inheritance.
openscientist CONCORDANT 90% In 85% of patients, the disease results from mutations in the COL4A5 gene located on X chromosome
OpenScientist gives the same ~80-85% X-linked predominance and enumerates the AR, AD, and digenic forms.
PMID:16895672

Alport syndrome presents as a kidney-ear-eye triad: persistent hematuria progressing through proteinuria to end-stage renal disease, plus sensorineural hearing loss and ocular abnormalities (notably anterior lenticonus and dot-and-fleck retinopathy).

UNANIMOUS INTEGRATED
phenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% A widely used clinical framing is the kidney–ear–eye triad: kidney disease with persistent haematuria progressing to CKD/kidney failure, plus hearing loss and ocular abnormalities.
Falcon states the classic kidney-ear-eye triad directly.
openscientist CONCORDANT 92% The disease manifests as progressive glomerular nephropathy—typically beginning with microscopic hematuria in childhood and advancing through proteinuria to end-stage renal disease (ESRD)—accompanied by sensorineural hearing loss and characteristic ocular abnormalities including anterior lenticonus and dot-and-fleck retinopathy.
OpenScientist describes the same triad and adds the specific ocular signs (anterior lenticonus, dot-and-fleck retinopathy).

Variant type is a major prognostic determinant: truncating COL4A5 variants are associated with markedly earlier kidney failure (median ESRD ~22 years) than non-truncating variants (median ~39 years).

MAJORITY INTEGRATED
genetic_factorprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% A strong relationship between transcript type and renal outcome was observed, with the median age of ESRD onset being 22 years for truncating mutations and 39 years for non-truncating mutations
OpenScientist quantifies the truncating-vs-non-truncating genotype-phenotype correlation with the pivotal cohort figures.
PMID:35020912
falcon PARTIAL 45% inheritance mode and variant type strongly influence risk of early kidney failure
Falcon affirms that variant type influences risk of early kidney failure and gives subtype/sex-based ESKD statistics, but does not report the specific truncating-vs- non-truncating median-ESRD split (22 vs 39 years).

The diagnostic hallmark on renal biopsy is progressive glomerular basement membrane ultrastructural change on electron microscopy — thinning evolving to thickening with multilaminar splitting ("basket-weave") — while light microscopy is often nonspecific.

UNANIMOUS INTEGRATED
diagnosispathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% Renal biopsy pathology shows GBM ultrastructural abnormalities (thinning/thickening, irregularity, lamellation/basket-weaving) on electron microscopy; light microscopy changes are often nonspecific (including FSGS).
Falcon describes the pathognomonic EM GBM changes and the nonspecific light-microscopy picture.
DOI:10.23876/j.krcp.24.063
openscientist CONCORDANT 90% Pathognomonic GBM changes — thinning (early), followed by thickening with multilaminar splitting of the lamina densa
OpenScientist reports the same pathognomonic thinning-then-basket-weave EM finding, with a 92.6% detection rate.
PMID:27596081

Early renin-angiotensin system blockade (ACE inhibitor/ARB) is the disease-modifying standard of care, slowing progression to kidney failure when started early.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 95% (ACE inhibitor or ARB) is the main disease-modifying standard of care, started early to slow progression.
Falcon states RAS blockade is the main disease-modifying standard of care.
DOI:10.1093/ndt/gfae265
openscientist CONCORDANT 93% Current treatment centers on early initiation of renin-angiotensin-aldosterone system (RAAS) blockade with ACE inhibitors, which can delay ESRD by years.
OpenScientist agrees RAAS blockade is the cornerstone therapy that delays ESRD by years.

SGLT2 inhibitors are an emerging add-on renoprotective therapy for proteinuric Alport patients, with the DOUBLE PRO-TECT Alport trial (NCT05944016) evaluating dapagliflozin in young patients.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% may be added in adults with proteinuria and chronic kidney disease.
Falcon cites the ERKNet/ERA/ESPN guideline that SGLT2 inhibitors may be added in proteinuric adults, and names the DOUBLE PRO-TECT Alport (NCT05944016) dapagliflozin trial.
DOI:10.1093/ndt/gfae265
openscientist CONCORDANT 88% The DOUBLE PRO-TECT Alport trial (NCT05944016) is currently evaluating SGLT2 inhibitor dapagliflozin in young AS patients.
OpenScientist independently reports the same DOUBLE PRO-TECT trial and frames SGLT2 inhibition within an emerging RAAS/SGLT2/nonsteroidal-MRA triple therapy.
PMID:39122650

Female carriers of X-linked Alport syndrome are not merely benign carriers but carry substantial lifetime disease burden, including high rates of hematuria and proteinuria and a meaningful risk of progression to kidney failure.

MAJORITY INTEGRATED
phenotypeprognosis
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Female carriers of X-linked AS were historically considered mildly affected, but contemporary evidence reveals that up to 95% develop hematuria, 75% develop proteinuria, and approximately 12–20% progress to kidney failure.
OpenScientist quantifies female-carrier burden (95% hematuria, 75% proteinuria, 12-20% kidney failure) from the ECASCA and Korean cohorts.
PMID:14514738, PMID:37100867
falcon PARTIAL 50% Females with XLAS are not just
Falcon makes the same qualitative point that XLAS females are not just carriers (estimating up to 25% progress to CKD G5), but reports lower/less granular figures than OpenScientist.

Bardoxolone methyl (CARDINAL trial) produced short-term eGFR gains but failed to demonstrate nephroprotection on hard outcomes and raised safety concerns, and was not FDA-approved.

SINGLE LEAD
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 90% However, a detailed commentary emphasizes lack of demonstrated nephroprotection on hard outcomes and substantial safety signals
Falcon details the CARDINAL efficacy signal, the offsetting safety concerns (equal kidney-failure counts, liver-enzyme elevations), and the FDA rejection.
DOI:10.1159/000529471
openscientist SILENT —
OpenScientist does not discuss bardoxolone methyl or the CARDINAL trial, focusing its emerging-therapy coverage on triple therapy, anti-IL-11, and gene editing.

Narrative

Overview

Both providers frame Alport syndrome as a monogenic type IV collagen basement-membrane disease driven by COL4A3/COL4A4/COL4A5 variants, presenting with a kidney-ear-eye triad and progressing from hematuria through proteinuria to end-stage renal disease. Falcon is guideline- and trial-registry-oriented (ERKNet/ERA/ESPN guidance, ClinicalTrials.gov records), while OpenScientist is broader and more mechanistic, integrating over 60 publications across genotype-phenotype, pathogenesis, animal models, and emerging therapy.

Agreement

The reports converge strongly on the core biology: the alpha3-alpha4-alpha5(IV) collagen defect, X-linked predominance (~80-85%) alongside AR/AD/digenic forms, the clinical triad, the pathognomonic basket-weave GBM change on electron microscopy, RAS/RAAS blockade as the disease-modifying standard of care, and SGLT2 inhibitors (DOUBLE PRO-TECT, NCT05944016) as an emerging add-on. Both also recognize that female X-linked carriers carry real disease burden.

Divergence

OpenScientist contributes quantitative genotype-phenotype detail (truncating vs non-truncating median ESRD 22 vs 39 years; glycine-substitution severity), quantified female-carrier burden (ECASCA/Korean cohorts), a detailed downstream cascade (ectopic laminin alpha2, IL-11/TGF-beta fibrosis, USAG-1/BMP-7), animal-model and carrier-prevalence data. Falcon uniquely details the bardoxolone methyl CARDINAL trial (efficacy signal vs safety/outcome concerns and FDA rejection) and the miR-21/lademirsen program. Quantitative differences (e.g., female renal-failure risk figures, prevalence framing) are coverage/ granularity gaps rather than contradictions.

Integration

Promoted to the disorder entry: the COL4A3/4/5 alpha3-alpha4-alpha5(IV) driver mechanism and GBM pathogenesis, the inheritance-form spectrum with X-linked predominance, the kidney-ear-eye phenotype set, the truncating-vs-non-truncating prognostic split, the basket-weave EM diagnostic hallmark, RAAS blockade as standard of care, and SGLT2 inhibitors/DOUBLE PRO-TECT as emerging therapy.

Not integrated (leads)

Retained as research leads rather than curated mechanisms: bardoxolone methyl/CARDINAL (investigational, FDA-rejected), the miR-21/lademirsen and anti-IL-11 programs, gene-editing approaches, and the detailed downstream fibrosis signaling (IL-11/TGF-beta, USAG-1/BMP-7), pending primary-literature verification.

Cross-provider synthesis comparing the falcon (guideline/registry-oriented) and openscientist (comprehensive, mechanistic) deep-research reports for Alport syndrome. No direct contradictions were found; divergence is coverage/granularity (OpenScientist adds quantitative genotype-phenotype and mechanistic depth; Falcon adds the bardoxolone/CARDINAL and miR-21/lademirsen trial detail). best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets were intentionally left unpopulated pending fetch-reference verification of the underlying PMIDs/DOIs.